Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus - Wikidata - awgldk - TriplyDB

Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus

Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus

http://www.wikidata.org/entity/Q57216969

about

High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms Arterial distensibility in chronic inflammatory rheumatic disorders Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.Systemic inflammation and early atheroma formation: are they related?The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis.Cardiac manifestations of rheumatological conditions: a narrative review Semiquantified noncalcified coronary plaque in systemic lupus erythematosus.Establishing the diagnosis of Libman-Sacks endocarditis in systemic lupus erythematosus D-dimer level and the risk for thrombosis in systemic lupus erythematosus.The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus.Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.European Forum on Antiphospholipid Antibodies: research in progress.Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review.Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.Libman-Sacks endocarditis as the first manifestation of systemic lupus erythematosus in an adolescent, with a review of the literature.Valvular heart disease in antiphospholipid syndrome.Pulmonary hypertension in antiphospholipid syndrome.Mitral Valve Perforation in Libman-Sacks Endocarditis: A Heart-Wrenching Case of Lupus Anti-Ro/SSA antibodies are associated with severe mitral valve regurgitation in patients with systemic lupus erythematosus.Case 1: Acute chorea.Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematous.Is it antiphospholipid syndrome?Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.Features associated with cardiac abnormalities in systemic lupus erythematosus.Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.Influence of systemic lupus erythematosus on procedure selection and outcomes of patients undergoing isolated mitral valve surgery.Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels.Pulmonary arterial hypertension in SLE: what do we know?Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies.Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study.

P2860

Q26774658-1D83E0C3-D5F3-4708-BC55-2F54DB0BE6DA Q30481548-234B7712-8FA4-4FFB-A1C1-796856E3BAF3 Q33387473-D67A369A-C386-4E03-929A-0868E741A62F Q34005307-27278C33-BBE3-475C-82EA-FEED793C2086 Q35154761-0A191692-8E35-45AC-89C4-338DBBFBCC88 Q35169351-971DCECC-DFD6-40F8-B639-445957517AD3 Q35209597-04A31466-42FE-4EA7-8B44-69FAFA8B2B3C Q35953555-2ED69AA2-9EAA-4F25-BC79-D196676DC3F8 Q36346769-E88B9691-0C36-41B8-9537-0AA406A66175 Q36355415-C6EDB15F-9CEC-48D4-ADD6-27295523E558 Q36709328-3D517E76-FFD3-4699-862D-7CA8013424FC Q36840557-FAB8F540-E1AD-4306-962A-BED9D6638C21 Q36947358-A4FB267E-CB56-4456-A7D0-26A2E8D25015 Q37206876-154A00AD-A653-44E9-81F3-EEB1841B4AE1 Q37206944-39EE1816-B381-442E-975C-FD41379CDE6F Q37578126-E3AEC239-4E96-4C8C-B862-1D769AE737F8 Q37826101-A761A74F-5347-4704-88C3-D92C9452E41B Q37853050-8B07EC28-58AE-4AF4-A523-EE57FEED8E7F Q38027000-7522531E-CBFB-4733-AF46-EB612926D074 Q38086166-49F192DE-188E-45E2-A836-6619D1127127 Q38325716-14E816CB-0327-4202-A51D-784FECBC592B Q38774615-3663D286-4FB4-4801-A6C7-EC5EA6804FE5 Q38899667-F9735345-F021-422F-B4D5-851A1D7D305D Q39421351-0419B43A-67D2-4115-AF7B-4CD81D22CA0D Q42364232-447D1A40-A995-4ABB-99ED-44C442D6E05C Q42591326-666435C7-0BAB-4408-88E5-48264F519357 Q44490545-63D564FD-B912-49AF-9690-5AFF37E8AC2C Q46118003-B343879A-9E5F-49A3-9BBB-C9063B9E7A8E Q50052184-DBDCB034-06B5-4324-A618-048F11189293 Q51361404-CCA6DDE1-32F2-46D4-B8A3-264D6B382471 Q52357267-E4CCB9D9-1197-428F-A008-1871858E62BA Q53102154-C567C224-0952-48D8-B9F0-0ACDF2D356FE Q53159273-3BB65F56-C5FA-4BCA-9578-3450BCEB84CA Q54052789-2BE084F6-92B7-4E0A-8AF9-1E49FAE368AD Q54963891-653C2ADB-FC34-4A63-93A6-68B2B04AD5A3

P2860

Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus

http://www.wikidata.org/entity/Q57216969

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2006

@uk

name

Relationship of antiphospholip ...... f systemic lupus erythematosus

@en

Relationship of antiphospholip ...... f systemic lupus erythematosus

@nl

type

label

Relationship of antiphospholip ...... f systemic lupus erythematosus

@en

Relationship of antiphospholip ...... f systemic lupus erythematosus

@nl

prefLabel

Relationship of antiphospholip ...... f systemic lupus erythematosus

@en

Relationship of antiphospholip ...... f systemic lupus erythematosus

@nl

P1433

Q57216969-3BE72083-833C-476E-ABF0-6BBBEAA76A3A

P1476

Q57216969-2239143B-3DC0-4517-B173-EDC875C49759

P2093

Q57216969-3AE9A20F-BE49-4ACA-BDF0-ADF00112CB21

Q57216969-3DFA0ADC-BD50-4E73-BAA9-B7EA1C80567E

Q57216969-58184996-17BF-4781-A128-52B553DCCEBC

Q57216969-5E41FDFB-536A-4CD4-92F8-604911DEA2D5

Q57216969-8AC3A0EA-CFDC-4880-AF90-48417EA6B5C8

Q57216969-A96FA783-A095-4BE8-8B23-FC14AD126725

Q57216969-B1A79726-26FD-4EB3-BA66-B60576DE3D54

Q57216969-C3E39184-F6C5-47CC-A8EE-3FEA5ED4AB6F

P2860

Q57216969-18B9D28D-FC0D-4636-A2C9-72AFC59ACB51

Q57216969-232E485F-2891-4016-B776-6DAC78EEB633

Q57216969-332146AE-951F-4C60-A2D6-84B41F695A27

Q57216969-67B3AA42-6AD5-40E2-AB71-5DE4535F559F

Q57216969-A7ACC606-7EE2-43DD-9AA3-95B97981FB68

Q57216969-BDE2D7AA-3B3C-4D08-9424-DABE9A5DBE89

P304

Q57216969-FECF89B1-19CE-4498-9ED7-27BDE48AE388

P31

Q57216969-6EF4E1A4-0233-4679-8E6F-EA51FBA0364E

P356

Q57216969-50D4090C-CCF0-47E3-8A58-119E54768517

P407

Q57216969-236C3904-D9F3-4206-B282-877C69378E8D

P433

Q57216969-D0E4F764-E5E1-43D2-A117-6816BDDEA3D6

P478

Q57216969-9A7D96A2-B15D-43E7-9966-064D708A9516

P50

Q57216969-7943D438-3F5F-488A-984F-A55F85EC24F8

Q57216969-CE5B6E70-D21D-4C51-AE72-E628478FD934

P577

Q57216969-79EFFE83-A39D-4225-B063-6D636753A3AC

P698

Q57216969-DB1E5CDC-E449-46C5-91A3-40466547289B

P921

Q57216969-1E21C46D-0625-4116-9907-59DEE6C81ADB

Q57216969-3F8806BB-E0EF-4A69-90B5-365D037FC21F

P356

P1433

Arthritis and Rheumatism

P1476

Relationship of antiphospholip ...... f systemic lupus erythematosus

@en

P2093

Adrienne Davis

http://www.w3.org/2001/XMLSchema#string

Afshin Farzaneh-Far

http://www.w3.org/2001/XMLSchema#string

Daniel M Levine

http://www.w3.org/2001/XMLSchema#string

Jane E Salmon

http://www.w3.org/2001/XMLSchema#string

Lisa Sammaritano

http://www.w3.org/2001/XMLSchema#string

Mary J Roman

http://www.w3.org/2001/XMLSchema#string

Mary K Crow

http://www.w3.org/2001/XMLSchema#string

Stephen A Paget

http://www.w3.org/2001/XMLSchema#string

P2860

Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis.

Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies.

IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.

A HITHERTO UNDESCRIBED FORM OF VALVULAR AND MURAL ENDOCARDITIS

Transesophageal Echocardiography

P304

3918-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.22265

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Michael D. Lockshin

Richard B Devereux

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17133599

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio